Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two vs Three Cycles of Induction Chemo-Immunotherapy in NPC
NCT06811844Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Response. Started Feb 2025; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06811844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06811844.